Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
2.930
-0.120 (-3.93%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Gain Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 113 | 57 | 49 | 37 | 65 | - | |
| Market Cap Growth | 87.16% | 16.03% | 32.75% | -42.34% | - | - | |
| Enterprise Value | 104 | 46 | 38 | 13 | 25 | - | |
| Last Close Price | 2.93 | 2.16 | 3.27 | 3.13 | 5.43 | - | |
| PS Ratio | - | - | 894.85 | 280.42 | 481.65 | - | |
| PB Ratio | 17.84 | 7.81 | 3.93 | 1.97 | 1.85 | - | |
| P/TBV Ratio | 19.45 | 7.95 | 3.99 | 1.99 | 1.86 | - | |
| EV/Sales Ratio | - | - | 691.99 | 96.63 | 186.53 | - | |
| Debt / Equity Ratio | 0.10 | 0.09 | 0.08 | 0.07 | 0.05 | 0.20 | |
| Net Debt / Equity Ratio | -1.39 | -1.33 | -1.25 | -1.10 | -1.01 | -1.00 | |
| Net Debt / EBITDA Ratio | 0.47 | 0.48 | 0.71 | 1.17 | 2.55 | 1.80 | |
| Net Debt / FCF Ratio | 0.47 | 0.52 | 0.84 | 1.41 | 2.83 | 1.91 | |
| Asset Turnover | - | - | 0.00 | 0.00 | 0.01 | - | |
| Quick Ratio | 2.30 | 2.85 | 3.44 | 4.93 | 14.53 | 3.58 | |
| Current Ratio | 2.52 | 2.97 | 3.59 | 5.11 | 14.78 | 4.25 | |
| Return on Equity (ROE) | -261.72% | -204.95% | -141.57% | -65.52% | -67.73% | -124.39% | |
| Return on Assets (ROA) | -86.79% | -82.80% | -65.14% | -35.24% | -35.60% | -42.37% | |
| Return on Capital Employed (ROCE) | -258.70% | -247.90% | -162.90% | -89.10% | -38.00% | -46.50% | |
| Earnings Yield | -17.21% | -35.63% | -45.10% | -47.29% | -21.53% | - | |
| FCF Yield | -15.35% | -32.98% | -38.24% | -39.82% | -19.32% | - | |
| Buyback Yield / Dilution | -54.44% | -75.86% | -9.49% | -16.90% | -279.11% | -19.17% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.